About Us
Dr. Bhooshan Zade
Oncologist in camp, Pune
“ Director, Dept of Radiation Oncology, Ruby Hall Clinic, Pune”
“ Head, Dept of Radiation Oncology, Indrayani Hospital, and Cancer Institute, Alandi (Devachi) Pune”
Dr Bhooshan Zade is a postgraduate in Radiation Oncology from the prestigious Tata Memorial Hospital, Mumbai. He has had extensive training in Clinical Oncology and High Precision Radiotherapy like SRS/SRT/IMRT/3DCRT during his resident ship. His areas of interest in CNS tumors and Interstitial Brachytherapy for Breast, Gynae, and Soft tissue sarcomas. He is giving treatment as an experienced Oncologist in Camp, Pune.
He topped the University in MD examinations conducted by the Maharashtra University of Health Sciences. He has given several oral and poster presentations in National Radiotherapy Conferences (AROI 2008 and 2009) and has won Travel Fellowship Award in Hyderabad AROI 2009.
- MD. Radiation Oncology. Tata Memorial Hospital, Mumbai, India (June 2009)
- DNB. Radiation Oncology. National Board of Examination, New Delhi (May 2010)
- PDCR. Professional Diploma In Clinical Research, Catalyst Clinical Services, Delhi (2007)
- MBBS, Govt. Medical College. Nagpur MS (Dec 2004)
AWARDS RECIEVED :
- University Topper in Maharashtra University of Health Sciences in MD Radiation Oncology examination held in May 2009
- “Travel Fellowship Award” at AROICON 2009 held at Hyderabad
- 11th Merit in HSC examination
- Received National Scholarship award in 1993
- Received Nayodaya Vidyalaya scholarship award in 1991
PROFESSIONAL SKILLS :
- Trained in various aspects of High Precision Radiotherapy like IMRT, IGRT, SRS, SCRT and 3DCRT along with experience of high end teletherapy machines like Tomotherapy and Trilogy.
- Extensively trained in 2D Conventional Radiotherapy and various aspects of Clinical Oncology
- High interest in Interstitial Brachytherapy especially for Ca Breast, Soft Tissue Sarcoma and Gynecologic malignancies.
- University Topper in Maharashtra University of Health Sciences in MD Radiation Oncology examination held in May 2009
- “Travel Fellowship Award” at AROICON 2009 held at Hyderabad
- 11th Merit in HSC examination
- Received National Scholarship award in 1993
- Received Nayodaya Vidyalaya scholarship award in 1991
- Dosimetric and feasibility study of IMRT using Helical Tomotherapy for Craniospinal Irradiation
- Early toxicity analysis of patients treated with Helical Tomotherapy for Craniospinal Irradiation.
- mpact of Image Guidance to validate differential PTV margins in Tomotherapy based treatment of craniospinal axis
- Cardiac sparing radiotherapy in carcinoma breast
1. Isolated Non-Hodgkin’s Lymphoma of Pancreas : Case report and review of literature. Ayan Basu, Nikhilesh Patil, Pranshu Mohindra, Bhooshan zade, Sumeet Gujral, MaryAnn Muckaden and Siddhartha Laskar. J Cancer Res Ther – Dec 2007 vol 3 Issue 4
2. Primary PNET of Maxilla: : An unusual presentation Mohindra, Pranshu; Zade, Bhooshan; Basu, Ayan; Patil, Nikhilesh; Viswanathan, Seethalakshmi; Bakshi, Ashish; Muckaden, Mary Ann; Laskar, Siddhartha. Journal of Pediatric Hematology/Oncology June 2008 – Volume 30 – Issue 6 – pp 474-477
1) Platinum SPARK: Protocol No. P276-00/64/11 “A Multicenter, Phase II/III Study to Assess Radiation Induced Mucositis in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Administered Cisplatin and Radiation with or without P276-00 .
2) Protocol :-RC/0111/009 : A Multicentre ,randomized,open label,single dose,two treatment, three period, three sequence,partial,replicate,cross- over ,pivotal bioequivalence,study of test capacitabine 500 mg tablet manufactured by Reliance life Sciences .pvt.Ltd., India with Xeloda (Capacitabine 500 mg ) manufactured by Roche Pharma, AG , Germany in adult, human cancer patients under fed condition.
3) BI LUX- Head & Neck 2: A randomized, double blind, placebo- controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma.